Cite
Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study
MLA
Cattaneo, Dario, et al. “Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 Mg by Swallowing Versus One Dose of 800 Mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study.” Therapeutic Drug Monitoring, vol. 37, no. 1, Feb. 2015, pp. 119–25. EBSCOhost, https://doi.org/10.1097/FTD.0000000000000114.
APA
Cattaneo, D., Cossu, M. V., Fucile, S., Riva, A., Baldelli, S., Meraviglia, P., Landonio, S., Impagnatiello, C., Resnati, C., Galli, M., Clementi, E., Capetti, A., Rizzardini, G., & Gervasoni, C. (2015). Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study. Therapeutic Drug Monitoring, 37(1), 119–125. https://doi.org/10.1097/FTD.0000000000000114
Chicago
Cattaneo, Dario, Maria V. Cossu, Serena Fucile, Agostino Riva, Sara Baldelli, Paola Meraviglia, Simona Landonio, et al. 2015. “Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 Mg by Swallowing Versus One Dose of 800 Mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study.” Therapeutic Drug Monitoring 37 (1): 119–25. doi:10.1097/FTD.0000000000000114.